Recalls & Warnings October 12, 2005 Supplement Company to Pay $2 Million Penalty For Alleged Violations of FTC Order On October 12, 2005 the Federal Trade Commission (FTC) announced that under the terms of a consent decree approved by the it for submission by the U.S
Comparison with Standard Treatments Studies comparing BPC-157 to becaplermin (the active ingredient in Regranex, an FDA-approved treatment for diabetic foot ulcers) found BPC-157 produced superior results in several parameters
One reason BPC-157 has attracted scientific interest is its potential interaction with biological processes associated with connective tissues
It improves force transmission, joint stability, and recovery
University of Queensland researcher Dr Timothy Piatkowski said the findings were "pretty concerning"
Diet and Exercise This is more complicated than it sounds, and dismissing it is a mistake